OncoMatch/Clinical Trials/NCT06790602
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Is NCT06790602 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cemiplimab Plus Gemcitabine for pancreatic ductal adenocarcinoma (mpdac).
Treatment: Cemiplimab Plus Gemcitabine — This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma with SWItch/Sucrose Non-Fermentable (SWI/SNF) alterations who have already been treated with FOLFIRINOX (5-fluoruracil, leucovorin, irinotecan, oxaliplatin) or gemcitabine/nab-paclitaxel chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: ARID1A alteration
Required: ARID1B alteration
Required: PBRM1 alteration
Required: SMARCA4 alteration
Required: SMARCB1 alteration
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — for pancreatic ductal adenocarcinoma
One previous line of therapy for pancreatic ductal adenocarcinoma (NOT immunotherapy or cellular therapy)
Cannot have received: immunotherapy
One previous line of therapy for pancreatic ductal adenocarcinoma (NOT immunotherapy or cellular therapy)
Cannot have received: cellular therapy
One previous line of therapy for pancreatic ductal adenocarcinoma (NOT immunotherapy or cellular therapy)
Cannot have received: immune checkpoint inhibitor
History of immune checkpoint inhibitor therapy, ever.
Cannot have received: investigational therapy
Two or more lines of systemic or previous investigational therapy for metastatic pancreatic ductal adenocarcinoma
Lab requirements
Blood counts
ANC ≥ 1,500/μL; Platelet count ≥ 100,000/μL; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤ 1.5x ULN
Liver function
Total bilirubin ≤ 1.5x ULN (Gilbert's syndrome allowed); AST ≤ 3.0x ULN (≤5.0x ULN if liver metastases present); ALT ≤ 3.0x ULN (≤5.0x ULN if liver metastases present)
Cardiac function
QTcF average of triplicate ECGs <470 ms
Adequate bone marrow function: Absolute neutrophil count ≥ 1,500 cells per microliter; Platelet count ≥ 100,000 cells per microliter; Hemoglobin ≥ 9.0 grams per deciliter. Adequate hepatic function: Total bilirubin ≤ 1.5 times upper limit of normal (NOTE high bilirubin levels due to Gilbert's syndrome are allowed); Aspartate transaminase ≤ 3.0 times upper limit of normal (≤5.0 times upper limit of normal if liver metastases are present); Alanine transaminase ≤ 3.0 times upper limit of normal (≤5.0 times upper limit of normal if liver metastases are present). Adequate renal function: Serum creatinine ≤ 1.5 times upper limit of normal. Calculated corrected QT Interval (QTcF) average of the triplicate electrocardiograms <470 milliseconds.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Diego · La Jolla, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06790602 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, cellular therapy, immune checkpoint inhibitor disqualifies patients from enrollment.
Does this trial require ARID1A?
Yes, ARID1A alteration is a required biomarker for enrollment.
Does this trial require ARID1B?
Yes, ARID1B alteration is a required biomarker for enrollment.
Does this trial require PBRM1?
Yes, PBRM1 alteration is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages